<DOC>
	<DOCNO>NCT02005848</DOCNO>
	<brief_summary>A Phase II , Double-Blind , Randomized , Placebo-Controlled , Multicenter , Study Evaluating Efficacy Safety Human , Alpha-1 Antitrypsin ( AAT ) [ Glassia® ] Treatment New Onset Type-1 Diabetes . The study objective : - To assess efficacy intravenous AAT treatment new onset Type 1 Diabetes - To assess safety tolerability intravenous AAT new onset Type 1 Diabetes pediatric young adult population .</brief_summary>
	<brief_title>Phase II Study Evaluate Efficacy Safety Glassia® Type-1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Main Subject ( parent/guardian ) willing able sign inform consent Age 825 ( inclusive ) year Recently diagnose T1DM Basal Cpeptide ≥ 0.2 pmol/mL Positive least one diabetesrelated autoantibody Ability consent comply completion patient diary No significant abnormality serum hematology , serum chemistry No significant abnormality urinalysis No significant abnormality ECG For woman child bear potential , nonpregnant , nonlactating female patient Main IgA deficient subject Subjects receive active/ live virus vaccine within 4 week screen date Subjects receive treatment corticosteroid medication within 2 month prior screen immunosuppressant cytostatic agent within 6 month prior screen Individuals history severe immediate hypersensitivity reaction , include anaphylaxis , plasma product Clinically significant intercurrent illness Pregnant lactate woman Current use medication know influence glucose tolerance Current prior ( within last 60 day prior screen visit ) use metformin , sulfonylurea , glinides , thiazolidinediones , exenatide , liraglutide , DPPIV inhibitor amylin .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Type-1 Diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>